Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,858 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and safety of tepotinib in Asian patients with advanced NSCLC with MET exon 14 skipping enrolled in VISION.
Kato T, Yang JC, Ahn MJ, Sakai H, Morise M, Chen YM, Han JY, Yang JJ, Zhao J, Hsia TC, Berghoff K, Bruns R, Vioix H, Lang S, Johne A, Le X, Paik PK. Kato T, et al. Among authors: chen ym. Br J Cancer. 2024 Jun;130(10):1679-1686. doi: 10.1038/s41416-024-02615-9. Epub 2024 Apr 4. Br J Cancer. 2024. PMID: 38575731 Free PMC article. Clinical Trial.
High efficacy of erlotinib in Taiwanese NSCLC patients in an expanded access program study previously treated with chemotherapy.
Perng RP, Yang CH, Chen YM, Chang GC, Lin MC, Hsieh RK, Chu NM, Lai RS, Su WC, Tsao CJ, Hsia TC, Chen HC, Chen CH, Huang MS, Wang JL, Ho ML, Chung CY, Yu CJ, Chang WC, Kuo HP, Yu CT, Lin ZZ, Kao WY. Perng RP, et al. Among authors: chen ym, chen ch, chen hc. Lung Cancer. 2008 Oct;62(1):78-84. doi: 10.1016/j.lungcan.2008.02.023. Epub 2008 Apr 18. Lung Cancer. 2008. PMID: 18423781 Clinical Trial.
Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial.
Miller VA, Hirsh V, Cadranel J, Chen YM, Park K, Kim SW, Zhou C, Su WC, Wang M, Sun Y, Heo DS, Crino L, Tan EH, Chao TY, Shahidi M, Cong XJ, Lorence RM, Yang JC. Miller VA, et al. Among authors: chen ym. Lancet Oncol. 2012 May;13(5):528-38. doi: 10.1016/S1470-2045(12)70087-6. Epub 2012 Mar 26. Lancet Oncol. 2012. PMID: 22452896 Clinical Trial.
Randomized phase II trial of first-line treatment with pemetrexed-cisplatin, followed sequentially by gefitinib or pemetrexed, in East Asian, never-smoker patients with advanced non-small cell lung cancer.
Ahn MJ, Yang JC, Liang J, Kang JH, Xiu Q, Chen YM, Blair JM, Peng G, Linn C, Orlando M. Ahn MJ, et al. Among authors: chen ym. Lung Cancer. 2012 Aug;77(2):346-52. doi: 10.1016/j.lungcan.2012.03.011. Epub 2012 Apr 23. Lung Cancer. 2012. PMID: 22534669 Clinical Trial.
Erlotinib in patients with advanced lung squamous cell carcinoma.
Chiang CL, Tsai CM, Chou TY, Chen YM, Lai SL, Shih JF, Chiu CH, Lee YC. Chiang CL, et al. Among authors: chen ym. Cancer Chemother Pharmacol. 2013 Jan;71(1):203-8. doi: 10.1007/s00280-012-1997-5. Epub 2012 Oct 10. Cancer Chemother Pharmacol. 2013. PMID: 23053274
Predictive factors for EGFR-tyrosine kinase inhibitor retreatment in patients with EGFR-mutated non-small-cell lung cancer - A multicenter retrospective SEQUENCE study.
Chang GC, Tseng CH, Hsu KH, Yu CJ, Yang CT, Chen KC, Yang TY, Tseng JS, Liu CY, Liao WY, Hsia TC, Tu CY, Lin MC, Tsai YH, Hsieh MJ, Wu WS, Chen YM. Chang GC, et al. Among authors: chen ym, chen kc. Lung Cancer. 2017 Feb;104:58-64. doi: 10.1016/j.lungcan.2016.12.002. Epub 2016 Dec 14. Lung Cancer. 2017. PMID: 28213001 Clinical Trial.
2,858 results